Results 181 to 190 of about 20,886 (213)

Heart of the matter: A GP’s guide to cardiac myosin inhibitors

InnovAiT: Education and inspiration for general practice
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition. It causes hypertrophy of the heart muscle and left ventricular outflow tract obstruction. Hypertrophic cardiomyopathy (HCM) is one of the most prevalent inherited cardiac disorders, with more than 1400 mutations discovered.
Tamara Naneishvili, Wei Jun How, Ivo Andrade, Samantha Cummins, David Hutchings, Aneil Malhotra, Luigi Venetucci, Rhys Beynon, Andrew Michael Crean   +8 more
openaire   +3 more sources

Recent trend in the therapy of hypertrophic cardiomyopathy: Cardiac myosin inhibitors

2023
Cardiac myosin inhibitors are a new class of drugs that have recently been approved in obstructive hypertrophic cardiomyopathy. The main mechanism of action is to reduce the pathologically increased cardiac hypercontractility. Current drug therapies have not been demonstrated to modify the natural progress of the disease.
DEMİRKIRAN, Cahit, DEMİRYÜREK, Şeniz, DEMİRYÜREK, Abdullah Tuncay   +2 more
openaire   +1 more source

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure, 2023
John W. Ostrominski, Ruby Guo, Perry M. Elliott, Carolyn Y. Ho   +3 more
openaire   +1 more source

FDA okays first cardiac myosin inhibitor

Nature Biotechnology, 2022
openaire   +1 more source

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere. Aficamten reduces pathologic cardiac hypercontractility by selectively binding to an allosteric site on cardiac myosin.
Michael K. Pugsley, Darren T. Hwee, Brett R. Winters, Jingying Wang, Eva R. Chin, Bradley P. Morgan, Fady I. Malik   +6 more
openaire   +2 more sources

Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2022
openaire   +1 more source

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Expert Opinion on Investigational Drugs, 2023
Shiavax J Rao, Beani Forst, Amreen K Kanwal, Arjun Kanwal, Wilbert S. Aronow, Srihari S Naidu   +5 more
openaire   +2 more sources

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Cardiac Myosin-Specific Autoimmune T Cells Contribute to Immune-Checkpoint-Inhibitor-Associated Myocarditis

Cell Reports, 2022
Taejoon Won, Ninaad Lasrado, Mónica V Talor   +2 more
exaly  

Therapeutics and DNA Methylation Inhibitors

Medical Epigenetics, 2021
Shyamala C Navada
exaly